NeoTract: Need, Solution, and Evidence Requirements
Ted Lamson, co-founder and CTO of NeoTract, shares his philosophy on the evidence requirements for a quality-of-life solution like the NeoTract offering.
NeoTract: Proving Device Feasibility
Ted Lamson, co-founder and CTO of NeoTract, describes his approach to proving the feasibility of the company’s solution in humans before making a more substantial investment in development and testing.
NeoTract: Choosing a Location and Investigators for Its First-in-Human Study
Ted Lamson, co-founder and CTO of NeoTract, outlines some of the key factors NeoTract considered in setting up its first-in-human study.
NeoTract: Advantages of Conducting Early Studies Outside the U.S.
Ted Lamson, co-founder and CTO of NeoTract, comments on how it can sometimes be beneficial to conduct early clinical work outside the U.S.
NeoTract: Early Study Design and Publication
Ted Lamson, co-founder and CTO of NeoTract, shares his experience and some pointer on clinical study design and devising a publication strategy.
NeoTract: The Decision to Pursue a CE Mark
Ted Lamson, co-founder and CTO of NeoTract, explains why and when NeoTract decided to pursue a CE Mark.
NeoTract: CE Mark Experience
Ted Lamson, co-founder and CTO of NeoTract, describes how his company’s pursued a CE Mark.
NeoTract: Launching in Europe and Getting Value from Its CE Mark
Ted Lamson, co-founder and CTO of NeoTract, shares how and why his company undertook as selective European launch after receiving its CE Mark.
NeoTract: Preliminary Interactions with NICE
Ted Lamson, co-founder and CTO of NeoTract, explains when his company was approached by NICE and how it managed those interactions.
NeoTract: The NICE Decision and Its Impact
Ted Lamson, co-founder and CTO of NeoTract, discusses his technology’s initial NICE decision and the effect it has had on the company.
NeoTract: Pricing
Ted Lamson, co-founder and CTO of NeoTract, comments on pricing for medtech products.